Morgan Stanley Forecasts Strong Price Appreciation for Solventum (NYSE:SOLV) Stock

Solventum (NYSE:SOLV) had its target price hoisted by stock analysts at Morgan Stanley from $73.00 to $80.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 0.51% from the stock’s current price.

Several other research analysts have also commented on SOLV. Mizuho upped their price objective on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday. Piper Sandler lifted their price objective on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. The Goldman Sachs Group upped their price target on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday. Bank of America increased their price objective on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, February 26th. Finally, Wells Fargo & Company upped their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $79.86.

Solventum Price Performance

SOLV opened at $79.60 on Wednesday. The firm has a market cap of $13.75 billion and a price-to-earnings ratio of 28.95. Solventum has a 1 year low of $47.16 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock’s 50 day simple moving average is $73.02 and its 200 day simple moving average is $70.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Solventum by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company’s stock worth $1,074,591,000 after acquiring an additional 75,631 shares during the last quarter. Trian Fund Management L.P. increased its holdings in shares of Solventum by 18.8% in the 4th quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company’s stock worth $559,054,000 after purchasing an additional 1,336,564 shares in the last quarter. State Street Corp raised its stake in shares of Solventum by 3.1% in the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Solventum by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 3,460,405 shares of the company’s stock valued at $227,992,000 after purchasing an additional 112,686 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Solventum during the fourth quarter valued at $203,740,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.